Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
Subscribe to this blog's RSS feed using https://nestforia.com/blogs/news.atom
Breaking News:Today, Gilead said an open-label Phase 3 trial testing the therapy in severely ill patients found that those taking a 5-day or 10-day course of treatment led to similar results. At least 52% of participants taking either dosing regimen were discharged from the hospital after 14 days of treatment, and at least 53% of those patients were reported as reaching "clinical recovery."
This is a milestone of the treatment of COVID-19 and it provides a lot of hope that the opening up of most states will come true sooner than expected.
However, we still need to keep in mind that before the vaccine is out, we should still keep ourselves protected since the Remdesivir from Gilead can at most cure the disease (with unknown long-term side effects). Social distance and personal protective equipment (PPE) is going to be still needed in the foreseeable future.